

Noggin-Fc Fusion Protein Conditioned medium

Catalog N002 - 100 ml Lot 5257 Life Sciences Incubator Yalelaan 62 3584 CM Utrecht The Netherlands

Product: Noggin-Fc Fusion Protein, conditioned medium

Product code: N002

Batch: 5257

Concentration (mg/L): 19.8 (> 15)

(μM): 0.20 (based on the dimeric stoichiometry)

Volume / aliquot (ml): 100

Yield (mg): 2.0

Purity (%): > 50 (> 25) Endotoxin (EU/ml): <1 EU/ml (<10)

Bioburden: Negative

Label: N002

Noggin-Fc Fusion protein

Conditioned medium, Batch 5257

Buffer: Conditioned medium

Storage temperature (°C): -80

Stability: 1 year (if stored at indicated conditions)

Shipping: Dry ice

Project manager: Wieger Hemrika QC officer: Roland Romijn

RAP Romyn

PRODUCT USE LIMITATIONS, WARRANTY, DISCLAIMER

ImmunoPrecise Antibodies' products contain chemicals which may be harmful if misused. Due care should be exercised with all ImmunoPrecise products to prevent direct human contact. All products are intended For Research Use Only and ARE NOT ALLOWED FOR USE IN HUMANS. Each product is shipped with documentation stating specifications and other technical information. ImmunoPrecise products are warranted to meet or exceed the stated specifications. ImmunoPrecise obligation and the customer's sole remedy is limited to replacement of products free of charge in the event products fail to perform as warranted. ImmunoPrecise makes no other warranty and SPECIFICALLY DISCLAIMS AND EXCLUDES ALL OTHER WARRANTIES OF ANY KIND OR NATURE WHATSOEVER, DIRECTLY OR INDIRECTLY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, AS TO THE SUITABILITY, PRODUCTIVITY, DURABILITY, FITNESS FOR A PARTICULAR PURPOSE OR USE, MERCHANTABILITY, CONDITION, OR ANY OTHER MATTER WITH RESPECT TO IMMUNOPRECISE PRODUCTS. In no event shall ImmunoPrecise be liable for claims for any other damages, whether direct, incidental, foreseeable, consequential, or special (including but not limited to loss of use, revenue or profit), whether based upon warranty, contract, tort (including negligence) or strict liability arising in connection with the sale or the failure of ImmunoPrecise Antibodies products to perform in accordance with the stated specifications.

Version 06/2021 page 1/1